Showing results (351-360 of 445) with videos related to

Sort By:
Pageof 45
Neuro-Oncology|August 19, 2024
Enhancing neuro-oncology care through equity-driven applications of artificial intelligenceMulki Mehari, Youssef Sibih, Abraham Dada, et al.
Science Advances|March 10, 2023
Design of a minimal di-nickel hydrogenase peptideJennifer Timm, Douglas H Pike, Joshua A Mancini, et al.
Epigenomics|August 2, 2024
An assessment of compositional methods for the analysis of DNA methylation-based deconvolution estimatesAlexander Alsup, Emily Nissen, Lucas A Salas, et al.
Annals of Human Genetics|March 30, 2000
Y-chromosome specific YCAII, DYS19 and YAP polymorphisms in human populations: a comparative studyL Quintana-Murci, O Semino, E S Poloni, et al.
Oncotarget|June 12, 2020
Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002)Theodore Nicolaides, Kellie J Nazemi, John Crawford, et al.
Scientific Reports|March 23, 2017
Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating GliomaLlewellyn E Jalbert, Adam Elkhaled, Joanna J Phillips, et al.
Neuro-Oncology Practice|March 5, 2016
Understanding inherited genetic risk of adult glioma - a reviewTerri Rice, Daniel H Lachance, Annette M Molinaro, et al.
Medrxiv : the Preprint Server for Health Sciences|October 31, 2023
Genetic predisposition to altered blood cell homeostasis is associated with glioma risk and survivalLinda Kachuri, Geno A Guerra, George A Wendt, et al.
Neuro-Oncology|March 14, 2020
MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrenceRadhika Mathur, Yalan Zhang, Matthew R Grimmer, et al.
Neuro-Oncology|August 31, 2016
Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomideMichael Wahl, Joanna J Phillips, Annette M Molinaro, et al.
Pageof 45